搜索
查看: 4925|回复: 0

个性化免疫疗法与免疫组测序的结合(综述)

[复制链接]

5

主题

9

帖子

57

积分

版主

Rank: 7Rank: 7Rank: 7

积分
57
发表于 2017-6-24 20:53:55 | 显示全部楼层 |阅读模式

Pubmed 上搜了下repertoire sequencing,review排在第一篇的居然是“Personalized T cell-mediated cancer immunotherapy: progress and challenges
好吧,谁让个性化医疗火热,癌症免疫疗法火热呢:文章总的来说就是强调了以下几点
1. 个体化的新抗原(neoantigen)是一个重要的靶点,而且这种针对neoantigen的免疫疗法更安全更高效;
2. 那么跟sequencing有什么关系呢?就是因为这种新型疗法需要测序手段辅助寻找这种neoantigen和TCR,尤其是对于TMB low的癌症,TCR更可能成为免疫疗法的突破口;
3. 所以针对TMD high和low的两种情况提出了两种不同的筛选neoantigen的方案:
Highlights
Patient-specific mutated neoantigens are important targets of anti-tumor immunity.
Personalized immunotherapies that target neoantigens may be safer and more effective.
Personalizing T cell-mediated immunotherapies will require efficient platforms for neoantigen and T cell receptor discovery.
TCR repertoire analysis may be an inroad for identifying targets of immunity against low mutational burden cancers.
Personalized immunotherapies present novel regulatory and logistical challenges.

回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

QQ|手机版|小黑屋|生信技能树 ( 粤ICP备15016384号  

GMT+8, 2021-10-21 13:18 , Processed in 0.200557 second(s), 32 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.